NeuroTrauma Sciences Strengthens Team with the Addition of Dr. Kevin Pong, MBA – Chief Business Officer

NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company focused on creating revolutionary treatments for stroke and traumatic brain injury victims, is pleased to announce the addition of Kevin Pong, PhD, MBA as their new Chief Business Officer.

Dr. Pong brings a wealth of experience in the areas of global business development, licensing, and alliance management that will help NTS advance their innovative neuroprotective drugs and strategies. His strategic leadership is certain to propel NTS to the forefront of CNS injury therapeutics.

We are thrilled to add Kevin to our executive leadership team! His proven success in cultivating strong business relationships, coupled with his expertise in business development and partnering strategy, and background in neuroscience will benefit us immensely as we strive to advance our lead program NTS-104 in stroke through the clinic and fundamental work in traumatic brain injury. Carl Long, Chief Executive Officer, expresses enthusiasm on the new addition.

Dr. Pong has been a driving force behind multiple transformative transactions in biotech and pharmaceutical companies for over two decades. After a successful tenure as Chief Business Officer of Anima Biotech, he also served as Vice President of Business Development, Licensing, and Alliance Management at Summit Therapeutics, and also led CNS business development opportunities at Sunovion Pharmaceuticals.

With a B.S. in Biological Sciences, a Ph.D. in Neuroscience from the University of Southern California, and an MBA from Rutgers University, he has been an invaluable asset to the ever-evolving field of biotechnology and pharmaceuticals.

I am thrilled to have the opportunity to join the NTS team and to be able to contribute to the development of treatments for stroke and traumatic brain injury, two incredibly underserved diseases.

My enthusiasm for working in neuroscience and my extensive experience will be invaluable tools in realizing the great potential of NTS. I am eager to get started and make a real difference.

About NeuroTrauma Sciences

NeuroTrauma Sciences is on a mission to revolutionize the way we treat acquired brain injuries, such as ischemic stroke and traumatic brain injury (TBI). Millions of patients worldwide suffer from the cognitive, functional, and neurobehavioral effects of these devastating injuries, which have too few therapeutic options.

By applying cutting-edge insights from neuroscience and eliciting new opportunities from drug discovery, NTS is driving forward a pipeline of powerful candidates with the goal of significantly improving the quality of life for those affected.

Leave a Comment